Novocure Ltd (NVCR) is up more than +11% after the US FDA approved the company’s Optune Lua to treat metastatic non-small cell lung cancer in adults who have progressed on or after a platinum-based ...
A Prescription Drug User Fee Act target action date of June 13, 2025, has been set for the new drug application of ...
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
Investor's Business Daily on MSN2h
Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device.
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
Retired tennis star Serena Williams said she underwent a procedure to remove a benign branchial cyst "the size of a small ...
The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.
TenNor Therapeutics has raised over 300 million yuan ($41 million) in a series E round, led by AMR Action Fund, to advance ...
US stock futures traded in a stable manner Wednesday, steadying after the previous season’s tech-inspired losses as quarterly ...
NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback